On 17 January 2024 Samsung Bioepis released its fourth US Biosimilar Market Report. The quarterly report details recent prices of US-launched biosimilars, and market share and price trends. The report covers the US-approved biosimilars on 14 INNs, of which 45 have been approved (including three in Q4 2023) and 38 launched. Of note in relation to adalimumab, Samsung Bioepis points out that six months afterthe July 2023 launch of seven biosimilar products, biosimilar adoption in the US is at 2%.
On 18 April 2023, Samsung Bioepis released its first US Biosimilar Market Report, predicting that biosimilars will save US$181B in five years in the US. Its second report was published on 11 July 2023, and the third report was published on 10 October 2023.